HIV Reservoir Reduction With Interleukin-2

Summary

The purpose of this pilot study is to examine the effects of eight 4-day cycles of subcutaneous recombinant interleukin-2 (rIL-2) given every 8 weeks on levels of replication-competent HIV in CD4 cells and on the size of HIV viral reservoir in up to 20 participants with chronically suppressed HIV infection (viral load \<50 copies/mL).

Timeline

Start

2019-04-01

Primary completion

2020-08-20

Completion

2020-08-20

Outcome

Outcome not reported

Stopped: “There were 3 instances of adverse events which were discussed with external safety monitoring committee and it was recommended that the study be terminated.”

Drugs

Indications